Talk DIAlogue Sessions track
S1101 - Inclusion of Underserved Populations in Clinical Trials
Thu, Mar 20, 2025 · 10:30–11:40 AM CET Sydney Room, Congress Center Basel
About this session
This session will explore global efforts to advance diversity, equity and inclusion in clinical trials, focusing on underserved populations and specifically women. Attendees will hear perspectives from regulatory authorities, industry and beyond with insights into key guidance, policy recommendations, and actionable steps for change.
The session will feature a keynote from EMA, covering its guidances and initiatives to advance clinical trial diversity. The keynote will be followed by a panel discussion on what underserved populations we should focus on, implications for not including underserved populations and what different stakeholders are doing to include those populations.
A second keynote will highlight policy recommendations for advancing women’s health in clinical research, followed by a panel discussion on the need to drive innovation in women-specific conditions and the need for the inclusion of women in trials as well as a “call for action” to drive meaningful change.
Both panel discussions will conclude with an interactive Q&A, offering attendees an opportunity to engage directly with the speakers and deepen their understanding of these critical issues.
Programme:
- 3. Keynote: Policy Recommendations to Prioritize, Protect, and Promote Women’s Health Research — Emily Fitzgerald, Anna Bode
- 1. Importance of Inclusion of Underserved Populations in Clinical Trials — Marina Malikova, Martin Hodosi
- 2. Panel Discussion - Navigating the landscape of underserved populations in Clinical Trials — Francesca Cerreta, Martin Hodosi, Sharon Denise Rivera Sanchez, Marina Malikova, Christine Mayer-Nicolai, Vaseeharan SATHIYAMOORTHY
- 4. Panel Discussion - Imperatives to drive inclusion and understanding of women in clinical trials — Shefali Goyal, Alison Cave, Anna Bode, Emily Fitzgerald, Christine Mayer-Nicolai
Speakers
-
Principal, Healthcare and Life Sciences Practices · Kearney
Chair
-
Principal · Kearney
Speaker
-
Chief Safety Officer · Medicines and Healthcare Products Regulatory Agency (MHRA)
Panelist
-
Head Global Regulatory and Scientific Policy · Merck KGaA
Panelist
-
Executive Director of Research, Assistant Professor of Surgery · Boston University School of Medicine
Chair
-
Initiatives Lead, Women's Health · World Economic Forum
Speaker
-
Vice President, Head of Global Product Regulatory Strategy & US RAaPV Lead · Organon
Panelist